Avis Budget Group (CAR) came out with quarterly earnings of $6.65 per share, missing the Zacks Consensus Estimate of $8.55 per share. This compares to earnings of $16.78 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -22.22%. A quarter ago, it was expected that this car rental company would post earnings of $2.60 per share when it actually produced earnings of $0.41, delivering a surprise of -84.23%.Over the last four quarter ...

Avis Budget Group Reports Third Quarter Results PARSIPPANY, N.J., October 31, 2024 - Avis Budget Group, Inc. (NASDAQ: CAR) announced financial results for third quarter 2024 today. We ended the quarter with revenues of nearly $3.5 billion, net income of $238 million, and Adjusted EBITDA of $503 million. 1 "We maintained a strong focus on pricing throughout the quarter, prioritizing higher margin business which allowed us to keep our revenue per day stable with the Americas nearly flat," said Joe Ferraro, Av ...

PARSIPPANY, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced financial results for third quarter 2024 today. We ended the quarter with revenues of nearly $3.5 billion, net income of $238 million, and Adjusted EBITDA1 of $503 million. “We maintained a strong focus on pricing throughout the quarter, prioritizing higher margin business which allowed us to keep our revenue per day stable with the Americas nearly flat,” said Joe Ferraro, Avis Budget Group Chief Executive Of ...

PARSIPPANY, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced today that it plans to report its third quarter 2024 results after the market close on Thursday, October 31st, 2024, and to host a conference call for institutional investors to discuss these results on Friday, November 1st, 2024 at 8:30 a.m. Eastern time. Investors may access the call at ir.avisbudgetgroup.com, or by dialing (877)-407-2991. Investors are encouraged to dial in approximately 10 minutes prior t ...

文章核心观点 - 生物技术市场近期受到经济压力和广泛情绪变化的威胁,Lyell Immunopharma公司面临十字路口 [1] - 公司正在采取雄心勃勃的道路来克服T细胞耗竭 [1] - 分析师擅长投资于高成长公司和颠覆性技术,采用基本面分析和未来趋势预测的方法 [1] 公司概况 - Lyell Immunopharma是一家生物技术公司,专注于开发能够克服T细胞耗竭的创新疗法 [1] - 公司正在采取雄心勃勃的道路来克服T细胞耗竭,这是一个关键的生物医学挑战 [1] 分析师观点 - 分析师擅长投资于高成长公司和颠覆性技术,采用基本面分析和未来趋势预测的方法 [1] - 分析师相信创新能带来可观的回报,并希望就此类公司提供深入的分析 [1]

Strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT’s multi-center Phase 1-2 clinical trial of IMPT-314 in patients with large B-cell lymphoma treated in the 3rd line CAR-naïve setting to be presented at a major medical conference later this year; initiation of a pivotal trial for IMPT-314 expected in 2025Lyell has prioritized its pipeline to focus on next-generation CAR T-cell therapies, including IMPT-314 and LYL119, ...

文章核心观点 - 西班牙是全球主要旅游目的地之一,吸引大量国内外游客,带动了当地汽车租赁市场的快速增长 [3][4] - 疫情后,西班牙旅游业呈现强劲反弹,2022年游客人数已超过疫前水平,带动汽车租赁需求大幅增加 [5] - 经济型车型和在线预订正成为西班牙汽车租赁市场的主流趋势 [6][7][8][9] - 行业内主要参与者包括Europcar、Hertz、Avis等知名租赁公司,他们不断推出新服务以满足客户需求 [10] 行业和公司研究总结 行业发展趋势 1. 旅游业的蓬勃发展是推动西班牙汽车租赁市场增长的主要动力 [3][4] 2. 疫情后西班牙旅游业呈现强劲反弹,带动汽车租赁需求大幅增加 [5] 3. 经济型车型和在线预订正成为市场主流趋势 [6][7][8][9] 主要参与企业 1. 西班牙汽车租赁市场主要参与者包括Europcar、Hertz、Avis等知名租赁公司 [10] 2. 这些公司不断推出新服务,如Uber在西班牙推出创新的汽车租赁服务 [10]

Allogeneic, TSCM-rich dual CAR-T for the treatment of hematologic malignancies, including multiple myelomaNomination triggers $15 million milestone payment to Poseida, extending cash runway into early 2026Poseida Cell Therapy R&D Day to take place on Thursday, November 14 at 7 am PT / 10 am ETSAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with ...

Patient showed clinical activity after initial treatment, with necrosis, inflammation, and T cell infiltration observed in tumor biopsy from the lowest dose SAN JOSE, Calif., Oct. 15, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has administered the second dose of its CAR-T therapy to an individual patient. This follows a positive response after the initial treatment ...

文章核心观点 - 公司正在开展一项名为NEXICART-2的临床试验,评估其CAR-T疗法NXC-201在复发/难治性AL淀粉样变病患者中的安全性和有效性 [1][2][3] - NXC-201是目前唯一正在美国临床试验中研究用于复发/难治性AL淀粉样变的CAR-T疗法 [1][2][4] - 在之前的NEXICART-1临床试验中,NXC-201已显示出高的总体和完全缓解率,且无神经毒性和细胞因子释放综合征持续时间短 [6][9] - 公司已获得FDA和EMA的孤儿药资格认定,表明NXC-201在AL淀粉样变治疗领域具有潜力 [7][9] 根据相关目录分别进行总结 临床试验进展 - 公司正在进行NEXICART-2临床试验,这是一项开放标签、单臂、多中心的I/II期剂量扩展试验,预计将入组40例复发/难治性AL淀粉样变患者 [5] - NEXICART-2试验设计包括6例安全性运行期,评估150百万和450百万CAR+T细胞两个剂量,后续将在450百万CAR+T细胞剂量进行扩展 [5] - 这些剂量水平在之前的NEXICART-1试验中已显示出完全缓解 [4][5] 临床数据 - NEXICART-1试验的初步数据显示,NXC-201在复发/难治性AL淀粉样变患者中取得了92%的总缓解率和28.0个月的缓解持续时间 [3] - NXC-201未出现任何神经毒性,细胞因子释放综合征持续时间也较短 [6][9] 市场机会 - AL淀粉样变是一种由异常的浆细胞产生的致病蛋白在心脏、肾脏和肝脏等器官中沉积而导致的疾病,目前在美国约有33,277例患者 [8] - 淀粉样变市场预计将从2017年的36亿美元增长到2025年的60亿美元 [8] 公司概况 - 公司是一家临床阶段的生物制药公司,专注于开发用于治疗AL淀粉样变和特定免疫介导性疾病的细胞疗法 [9] - NXC-201是公司的领先候选药物,已获得FDA和EMA的孤儿药资格认定 [7][9]